More tools:Markets·Screener·Research Chat

Vertex Pharmaceuticals Inc (VRTX) Financial Statements

Vertex Pharmaceuticals Inc
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S68LJ8
XNAS · usd
476.31▼ 3.94 (-0.82%)
As of 2026-07-14
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)$12.2B
Net Income (TTM)$4.3B
EBITDA
Diluted EPS (TTM)
EBITDA Margin40.1%
Net Debt
Trading Information
Previous Close480.25
Day's Range473.18 – 481.29
52-Week Range362.50 – 533.67
Volume1.07M
Avg Volume1.71M
Share Statistics
Shares Outstanding253.8M
Employees6,400
ExchangeXNAS
Listed1991-07-31

Key questions about Vertex Pharmaceuticals Inc (VRTX)

What is Vertex Pharmaceuticals Inc's Market Cap?
Vertex Pharmaceuticals Inc's Market Cap is $120.9B, based on as-reported figures from SEC (XBRL) filings.
What is Vertex Pharmaceuticals Inc's Enterprise Value?
Vertex Pharmaceuticals Inc's Enterprise Value is $121.9B, based on as-reported figures from SEC (XBRL) filings.
What is Vertex Pharmaceuticals Inc's Trailing P/E?
Vertex Pharmaceuticals Inc's Trailing P/E is 27.9×, based on as-reported figures from SEC (XBRL) filings.
What is Vertex Pharmaceuticals Inc's Price / Sales?
Vertex Pharmaceuticals Inc's Price / Sales is 9.9×, based on as-reported figures from SEC (XBRL) filings.
What is Vertex Pharmaceuticals Inc's EV / Revenue?
Vertex Pharmaceuticals Inc's EV / Revenue is 10.0×, based on as-reported figures from SEC (XBRL) filings.
What is Vertex Pharmaceuticals Inc's EV / EBITDA?
Vertex Pharmaceuticals Inc's EV / EBITDA is 24.9×, based on as-reported figures from SEC (XBRL) filings.
What is Vertex Pharmaceuticals Inc's Revenue (TTM)?
Vertex Pharmaceuticals Inc's Revenue (TTM) is $12.2B, based on as-reported figures from SEC (XBRL) filings.
What is Vertex Pharmaceuticals Inc's Net Income (TTM)?
Vertex Pharmaceuticals Inc's Net Income (TTM) is $4.3B, based on as-reported figures from SEC (XBRL) filings.
What is Vertex Pharmaceuticals Inc's EBITDA?
Vertex Pharmaceuticals Inc's EBITDA is $4.9B, based on as-reported figures from SEC (XBRL) filings.
What is Vertex Pharmaceuticals Inc's Diluted EPS (TTM)?
Vertex Pharmaceuticals Inc's Diluted EPS (TTM) is 17.09, based on as-reported figures from SEC (XBRL) filings.
Loading Income Statement…
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Revenues:
Product revenues, net
Other revenues—
Total revenues
YoY growth+7.8%+9.5%+11.0%+12.1%
Costs and expenses:
Cost of sales
Research and development expenses
Acquired in-process research and development expenses
Selling, general and administrative expenses
Intangible asset impairment charge—
Change in fair value of contingent consideration
Total costs and expenses
% of revenue61.9%62.2%61.4%61.2%
Income from operations
% of revenue38.1%37.8%38.6%38.8%
Interest income, net———
Other expense , net—
Income before provision for income taxes
Provision for income taxes
Net income
% of revenue34.5%37.3%35.2%34.8%
Net income per common share:
Basic
Diluted
Shares used in per share calculations:
Basic
Diluted